Chinese patent medicine under the adjustment of the medical insurance directory: favorable policies densely introduced drive collection upgrade

The 21st Century Economic Herald reporter Tang Weiko's intern Yang Siqi Guangzhou reported that under the promotion of a favorable policy, the pace of Chinese patent medicine has been incorporated into the national medical insurance catalog and collection continued to accelerate in recent years.

After a week of publicity, on September 17, the State Medical Insurance Administration officially announced the "List of Application Drugs for Approval, Work Injury Insurance and Maternity Insurance Drug Catalogs in 2022". A total 198 types of catalogs and Chinese medicines and Chinese medicines and Chinese medicines in the catalog, including 15 Chinese medicines outside the directory, and 34 Chinese medicines in the directory. Compared with 2021 (the publication list is 8, there are 8 Chinese medicines outside the catalog, and the directory is inside the directory. 23 Chinese medicines) have been greatly improved.

In recent years, the policy dividends of the Pharmaceutical Insurance Payment Payment Performance Payment of Pharmaceuticals have continued to promote the proportion of Chinese medicines in the medical insurance directory. In 2019, the number of Chinese and western medicines in the national medical insurance directory was flat for the first time.

In addition, recently, the National Pharmaceutical Joint Procurement Office is officially established. The National Pharmaceutical National Collection will soon begin. The Hubei Provincial Medical Insurance Bureau is responsible for the daily work of the joint procurement office and is responsible for the specific implementation. On September 9th, the National Pharmaceutical Joint Procurement Office issued the "Announcement of Procurement of the National Chinese Pharmaceutical Alliance (2022)", marking the second round of the second round of the Chinese Pharmaceutical Alliance led by the Hubei Provincial Medical Security Bureau. The collection of Chinese medicines involves 16 kinds of medicines such as compound spots, compound thrombosis, crown heart, and Hua Toad Su.

Today, the trend of aging population has intensified, the base of patients with chronic diseases has continued to expand, and the rigid demand for Chinese medicine has also increased. Therefore, on the one hand, the price cost of reducing the proclaimed patent medicine through the collection side of the collection side; on the other hand, the medical insurance directory is dynamically adjusted to allow more innovative Chinese medicines to enter the medical insurance directory and reduce the cost of patients from the payment side.

In this regard, Zhao Heng, founder of the medical strategy consulting company Latitude Health, pointed out to the 21st Century Business Herald that the procurement of national tissue belt is mainly to reduce the price of drugs and allow more new drugs to enter medical insurance. The development of Chinese medicine collection will definitely have a impact on Chinese medicine companies, but it can promote them to transform and upgrade. This is divided into two paths: one is to make consumer products, mainly non -medical insurance products; one is to develop new Chinese medicines.

Zhong Ya Yaosheng Medical Insurance Welcome to the Acceleration

In recent years, under the promotion of national revitalization of traditional Chinese medicine, various favorable policies have been introduced densely.

The "Opinions on Promoting the Innovation and Development of Chinese Medicine inheritance and Innovation and Development on October 26, 2019" proposed that vigorously developing traditional Chinese medicine clinics, unique varieties of screening effects, promoting the improvement of the quality of traditional Chinese medicine, promoting the improvement of the quality of Chinese medicine tablets and the quality of Chinese medicine, reform and improvement of traditional Chinese medicine registration Management, strengthening the quality and safety supervision of traditional Chinese medicine, improving the price of traditional Chinese medicine and medical insurance policy, strengthening the prevention of traditional Chinese medicine, rehabilitation, promoting the scientific research of traditional Chinese medicine, and innovation of 20 development opinions, pointing out the direction for the development of traditional Chinese medicine inheritance in the future.

On December 30, 2021, the "Guiding Opinions on Medical Insurance Supporting the Innovation of Traditional Chinese Medicine inheritance and Innovation Development" jointly issued by the State Medical Insurance Administration and the State Administration of Traditional Chinese Medicine proposed to support the innovation and development of traditional Chinese medicine. Incorporating the eligible Chinese medicine, traditional Chinese medicine tablets, and traditional Chinese medicine hospitals are included in the scope of medical insurance payment, and it is pointed out that the Chinese medicine institution can not implement the DRG paid system at the same time, and the traditional Chinese medicine decoction tablets can continue to bonuse by 25%.

Judging from the final results of the national medical insurance directory adjustment in recent years, 23, 40 and 3 Chinese medicines were included in 2019-2021. After the national medical insurance directory was adjusted in 2021, the total number of drugs in the directory was 2,860, including 1,486 western medicines and 1,374 Chinese medicines. There are still 892 types of Chinese medicine drinks. Among them, the proportion of Chinese medicines accounts for nearly 50%.

At the same time, localities are also increasing the measures of Chinese patent medicines into medical insurance. On the basis of 892 Chinese medicine tablets of the National Pharmaceutical Catalog, Guangxi incorporated 531 Chinese medicines and national medicine drinks into Guangxi basic medical insurance (including maternity insurance) and the scope of work injury insurance funds. Essence

It is worth noting that, as the "modern" product of traditional Chinese medicine, the formula of traditional Chinese medicine formula is also accelerating the inclusion of medical insurance.

On August 31st this year, the State Medical Insurance Bureau issued the "Notice on Printing and Distributing the Unified Coding Rules and Methods of Medical Insurance Formula Granules." The notice shows that the unified encoding rules and methods of medical insurance formula formulas have been completed.

From the perspective of the industry, with the advancement of the unified standard of Chinese medicine formula particles, the identification of the provinces and medical insurance directory will further increase the determination of the Chinese medicine formula particles.

In addition, in December last year, the National Medical Insurance Bureau released the 2021 version of the medical insurance directory. At the same time, it was clear that 892 Chinese medicine drinks can be paid by medical insurance. Drugs with reasonable prices and exact effects are included in the scope of medical insurance payment.

As of now, many provinces such as Anhui, Zhejiang, Hebei, Hunan, Beijing, and Annex have incorporated Chinese medicine formula particles into the scope of medical insurance payment.

Strictly regulate that Chinese medicine and medical insurance payment

Under the favorable policies, the medical insurance directory has become more stringent to the norms of Chinese medicine. The specific manifestations are the restrictions on the control of Chinese medicine and the scope of Chinese medicine drugs and auxiliary medications.

In the 2019 version of the National Medical Insurance Catalog Publishing Notice, it is clearly that strict payment management must be proposed. The Chinese medicine prescription and prescription of Chinese medicine drinks prescribed by a physician with corresponding qualifications can be paid as prescribed. Each region of all coordinating areas shall establish a medical insurance agreement system to strengthen the management and management of the qualifications for prescriptions for doctors. Prior to this, the National Health and Health Commission had issued a notice to make a hard rule on the prescriptions of the Chinese medicine and medicines: non -traditional Chinese medicine and traditional Chinese medicine doctors, after less than one year to systematically study the professional knowledge of Chinese medicine and passed the assessment, follow the traditional Chinese medicine. The basic clinical syndrome differentiation principles can be prescribed for prescriptions of Chinese medicine.

On the other hand, the effectiveness and safety of Chinese medicine are controversial. In particular, the frequent visitor to the "auxiliary medication" catalog — traditional Chinese medicine injection is increasingly strictly supervised by the country and local.

Professor Zhu Wentao, a professor at Beijing University of Traditional Chinese Medicine, explained in an interview with the media that due to the complexity of traditional Chinese medicine injections, the uncertainty and allergic reactions of allergic reactions, there are many types of allergic reactions, and the adverse reactions of traditional Chinese medicine injections are unpredictable.

The 2020 version of the medical insurance catalog puts out clear requirements for the 32 -level Chinese medicine injection of some grassroots at the grassroots level. Only medical institutions above the second level can be used, and there are restrictions on the aspects of intensiveness and diseases. At the same time, the medical insurance qualifications for stirvania polyphenolic acid and red red injection were also canceled.

Not only that, under various specifications, many Chinese medicines have been "kicked out" the medical insurance directory.

In July 2019, the National Medical Insurance Bureau required provinces to gradually eliminate the supplementary drugs that did not match the province's medical insurance directory within three years in accordance with the ratio of 40%, 40%, and 20%. After that, the list of cleanup and supplementary supplements began to release.

The three -year retirement and replenishment action is close to the end. It is worth noting that from the perspective of the clean -up and additional drugs published in various places, Sino -patent medicine accounts for relatively large.

For example, Hebei Province did not call the original B -category B medicine directly from medical insurance. Instead, it was given priority to the scope of national and provincial key monitoring. However, 212 of the 498 drugs at that time were Chinese medicines. In June of this year, the list of replenishment drugs released by Guangxi was 168 medicines, of which 155 were Chinese medicine.

Chinese patent medicine collection trend

Compared with chemicals, Chinese patent medicines are difficult to collect for industry consensus. Because there are many exclusive varieties of Chinese medicine, in addition, the production process is different, and there is still a lack of consistency evaluation.

However, with the establishment of various standards and rules and local explorations, Chinese medicines have officially ushered in a breakthrough.

It is understood that the national collection has been appointed by as many as 30 alliance regions, including Hubei Province and Beijing, to form a joint procurement office of Chinese Pharmaceutical Pharmaceuticals. The objects involve 16 Chinese medicines such as compound spotted spots, compound thrombosis, crown heart, and Hua Toads.

The establishment of the National Medicine Pharmaceutical Joint Procurement Office will further promote the institutionalization, organizationalization, and normalization of drug collection and mining work, and promote the reunification and standardization of Sino -Pharmaceutical Medical Insurance reimbursement nationwide.

Prior to this, the Chinese medicine collection has been launched in many places. In December 2021, Hubei Province led 19 provinces and regions to form alliances and carried out a round of league medicine collection in the form of alliances. 97 companies and 111 products were selected. Basically, medicines with a large amount of medical insurance and drugs and high procurement amounts. This is the first time in the country's concentrated procurement of Sinopharmaceutical Alliance, and it is expected to save at least 2.6 billion yuan in drug costs each year.

Regarding the first Sino -Pharmaceutical Alliance collection initiated by Hubei Province, the National Medical Insurance Bureau introduced that 182 products of 157 enterprises participated in the quotation, and eventually 97 companies were selected in 111 products. The average selected price decreased by 42.27%, a maximum of 82.63%.

In April of this year, the Guangdong Pharmaceutical Exchange Center issued the "Notice of Publicizing the Procurement of China Pharmaceuticals and other Chinese Pharmaceutical Pharmaceuticals in the Guangdong Alliance. The collection alliance includes six provinces (districts (districts (districts (districts) in Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai. Blood Ning, Fangfang Danshen and other well -known products. Subsequently, Shandong Province and Beijing have also carried out the work related to procurement of Chinese patent patent band.

Zhao Heng emphasized to the 21st Century Business Herald that the national collection is mainly to reduce the price of drugs and allow more new drugs to enter medical insurance.

Over the years, there have been problems in the Chinese patent medicine industry. According to the medical prices of the State Medical Insurance Bureau and the head of the Bidding and Procurement Department, in recent years, in recent years, the state has strongly supported the development of Chinese medicine and Chinese medicine. It is equivalent to the recognition of unreasonable and aggravated virtual drug prices that increase the burden of the masses, and the particularity of the industry is not a shelter of virtual high drug prices.

Galaxy Securities believes that in the long run, the Chinese patent medicine collection has good resources with high -quality Chinese medicine leading enterprises, and the industry concentration is expected to continue to optimize. Chinese medicines lack clear standards in terms of indications, grouping, and processing methods. There is no unified evaluation mechanism. The increase in industry concentration helps the entire industry to establish a unified quality guarantee system.

- END -